Insider Transactions in Q3 2024 at Regenxbio Inc. (RGNX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2024
|
Mitchell Chan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,869
+50.0%
|
-
|
|
Sep 03
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,000
-24.77%
|
$110,000
$11.92 P/Share
|
|
Sep 03
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.96%
|
$30,000
$3.76 P/Share
|
|
Aug 08
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
36,316
+7.56%
|
$0
$0.85 P/Share
|
|
Aug 01
2024
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,386
+26.07%
|
-
|
|
Aug 01
2024
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,867
+24.13%
|
-
|
|
Aug 01
2024
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$1,500
$15.0 P/Share
|
|
Aug 01
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,100
-16.39%
|
$141,400
$14.35 P/Share
|
|
Aug 01
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,100
+16.21%
|
$80,800
$8.25 P/Share
|
|
Aug 01
2024
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,446
+24.69%
|
-
|
|
Jul 29
2024
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,648
-5.37%
|
$144,720
$15.04 P/Share
|
|
Jul 29
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
11,000
-49.36%
|
$165,000
$15.04 P/Share
|
|
Jul 29
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+33.05%
|
$132,000
$12.74 P/Share
|
|
Jul 25
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,369
-3.63%
|
$199,797
$13.96 P/Share
|
|
Jul 25
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,369
+3.5%
|
$46,107
$3.76 P/Share
|
|
Jul 24
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
12,221
-2.91%
|
$158,873
$13.78 P/Share
|
|
Jul 24
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
12,221
+2.83%
|
$36,663
$3.76 P/Share
|
|
Jul 17
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
2,210
-0.54%
|
$28,730
$13.77 P/Share
|
|
Jul 17
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
2,210
+0.54%
|
$6,630
$3.76 P/Share
|
|
Jul 16
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
200
-0.05%
|
$2,600
$13.76 P/Share
|
|
Jul 16
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.05%
|
$600
$3.76 P/Share
|
|
Jul 01
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,000
-46.98%
|
$110,000
$11.27 P/Share
|
|
Jul 01
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.96%
|
$30,000
$3.76 P/Share
|
|
Jul 01
2024
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,458
+23.9%
|
-
|